Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Werewolf Therapeutics, Inc. (HOWL)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues [+] | 1.0 | 1.3 | 1.2 | 0.6 | 0.1 | 0.0 | 0.0 | 0.1 |
| Net investment income | 1.0 | 1.3 | 1.2 | 0.6 | 0.1 | 0.0 | | 0.1 |
| Revenue growth | 924.7% | 3353.8% | | 998.1% | 90.2% | | | |
| Cost of goods sold | -7.1 | -3.1 | 6.1 | -4.4 | -4.1 | 0.0 | 0.0 | 0.1 |
| Gross profit | 8.1 | 4.5 | -4.9 | 5.0 | 4.1 | 0.0 | 0.0 | 0.0 |
| Gross margin | 813.0% | 331.4% | -417.7% | 838.1% | 4276.3% | 0.0% | | 0.0% |
| Selling, general and administrative [+] | 4.6 | 5.0 | 4.6 | 4.4 | 5.2 | 4.4 | 4.5 | 4.0 |
| General and administrative | 4.6 | 5.0 | 4.6 | 4.4 | 5.2 | 4.4 | 4.5 | 4.0 |
| Research and development | 9.6 | 11.7 | 15.9 | 13.1 | 13.9 | 10.9 | 13.4 | 9.8 |
| Other operating expenses | | | -12.2 | | | | | |
| EBITDA [+] | -5.6 | -11.8 | -12.8 | -12.1 | -14.8 | -15.3 | -17.8 | -13.7 |
| EBITDA growth | -61.9% | -22.7% | -28.4% | -11.6% | 35.7% | 106.0% | 142.7% | 128.3% |
| EBITDA margin | -566.7% | -875.9% | -1082.4% | -2046.4% | -15244.3% | -39148.7% | | -25422.2% |
| Depreciation and amortization | 0.4 | 0.4 | 0.4 | 0.4 | 0.2 | 0.1 | 0.0 | 0.1 |
| EBIT [+] | -6.1 | -12.2 | -13.2 | -12.5 | -15.0 | -15.4 | -17.9 | -13.8 |
| EBIT growth | -59.5% | -20.5% | -26.3% | -9.1% | 36.7% | 106.2% | 141.9% | 127.9% |
| EBIT margin | -610.4% | -907.4% | -1117.8% | -2114.5% | -15435.1% | -39400.0% | | -25546.3% |
| Interest income | | | | | | | 0.0 | |
| Interest income | | | | | | | 0.0 | |
| Other income (expense), net | 1.0 | 0.2 | 1.2 | 0.6 | 0.4 | 0.0 | | 0.0 |
| Pre-tax income | -5.1 | -12.0 | -11.9 | -11.9 | -14.6 | -15.3 | -17.9 | -13.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -5.1 | -12.0 | -11.9 | -11.9 | -14.6 | -15.3 | -17.9 | -13.8 |
| Net margin | -512.9% | -889.5% | -1011.9% | -2014.0% | -15045.4% | -39341.0% | | -25477.8% |
| |
| Basic EPS [+] | ($0.14) | ($0.34) | ($0.41) | ($0.40) | ($0.53) | ($0.56) | ($0.97) | ($0.51) |
| Growth | -73.0% | -38.5% | -57.3% | -20.7% | -86.1% | -99.3% | -95.3% | -92.3% |
| Diluted EPS [+] | ($0.14) | ($0.34) | ($0.41) | ($0.40) | ($0.53) | ($0.56) | ($0.97) | ($0.51) |
| Growth | -73.0% | -38.5% | -57.3% | -20.7% | -86.1% | -99.3% | -95.3% | -92.3% |
| |
| Shares outstanding (basic) [+] | 35.6 | 34.8 | 28.9 | 29.8 | 27.5 | 27.4 | 18.5 | 27.2 |
| Growth | 29.2% | 27.0% | 56.4% | 9.5% | 55.0% | 2128.9% | 1736.3% | 2861.7% |
| Shares outstanding (diluted) [+] | 35.6 | 34.8 | 28.9 | 29.8 | 27.5 | 27.4 | 18.5 | 27.2 |
| Growth | 29.2% | 27.0% | 56.4% | 9.5% | 55.0% | 2128.9% | 1736.3% | 2861.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|